Published in J Clin Oncol on July 18, 2005
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer (2007) 2.98
The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med (2009) 2.32
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol (2012) 2.01
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer (2009) 1.78
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol (2008) 1.74
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med (2007) 1.64
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res (2009) 1.56
The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo. Proc Natl Acad Sci U S A (2008) 1.53
Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J (2008) 1.41
Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol (2006) 1.40
Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia (2007) 1.33
Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts. Korean J Radiol (2012) 1.24
Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol (2007) 1.23
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol (2013) 1.21
Molecular imaging in cancer treatment. Eur J Nucl Med Mol Imaging (2010) 1.21
Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer (2006) 1.20
Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis (2010) 1.17
DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res (2009) 1.15
Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? Eur J Nucl Med Mol Imaging (2010) 1.14
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer (2012) 1.13
Non-invasive imaging for studying anti-angiogenic therapy effects. Thromb Haemost (2013) 1.12
Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development? J Clin Oncol (2005) 1.09
Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. Onco Targets Ther (2012) 1.08
DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy. Mol Imaging Biol (2011) 1.07
Axitinib for the management of metastatic renal cell carcinoma. Drugs R D (2011) 1.01
Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis Rev (2008) 0.98
Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis. Magn Reson Med (2009) 0.97
PET Imaging of Angiogenesis. PET Clin (2009) 0.94
Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies? Br J Cancer (2012) 0.93
Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin Med Insights Oncol (2013) 0.90
Feasibility of using limited-population-based average R10 for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced magnetic resonance imaging data. Magn Reson Imaging (2009) 0.89
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol (2012) 0.89
A model-constrained Monte Carlo method for blind arterial input function estimation in dynamic contrast-enhanced MRI: I. Simulations. Phys Med Biol (2010) 0.88
Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis. BMC Cancer (2014) 0.82
Comparison of quantitative parameters in cervix cancer measured by dynamic contrast-enhanced MRI and CT. Magn Reson Med (2010) 0.82
Magnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancer. Int J Hyperthermia (2010) 0.81
Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo. J Cancer Res Clin Oncol (2014) 0.81
Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol (2010) 0.81
Concise drug review: pazopanib and axitinib. Oncologist (2012) 0.81
Axitinib plasma pharmacokinetics and ethnic differences. Invest New Drugs (2015) 0.80
Imaging hemodynamics. Cancer Metastasis Rev (2008) 0.79
Dependence of DCE-MRI biomarker values on analysis algorithm. PLoS One (2015) 0.78
Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries. Mol Imaging (2014) 0.78
Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol (2015) 0.78
A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells. Ann Thorac Cardiovasc Surg (2009) 0.78
Translational imaging endpoints to predict treatment response to novel targeted anticancer agents. Drug Resist Updat (2011) 0.78
Dose-response relationship in cisplatin-treated breast cancer xenografts monitored with dynamic contrast-enhanced ultrasound. BMC Cancer (2015) 0.77
Usefulness of dynamic contrast-enhanced magnetic resonance imaging for predicting treatment response to vinorelbine-cisplatin with or without recombinant human endostatin in bone metastasis of non-small cell lung cancer. Am J Cancer Res (2016) 0.75
Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma. Br J Cancer (2013) 0.75
Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. Chin J Cancer (2016) 0.75
Applications of imaging technology in radiation research. Radiat Res (2012) 0.75
A method for limiting pitfalls in the production of enhancement kinetic curves in 3T dynamic magnetic resonance mammography. J Thorac Dis (2012) 0.75
Diagnostic value of dynamic contrast-enhanced magnetic resonance imaging in rectal cancer and its correlation with tumor differentiation. Mol Clin Oncol (2016) 0.75
CT spectral imaging for monitoring the therapeutic efficacy of VEGF receptor kinase inhibitor AG-013736 in rabbit VX2 liver tumours. Eur Radiol (2016) 0.75
Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI. Neoplasia (2017) 0.75
Magnetic resonance-imaging of the effect of targeted antiangiogenic gene delivery in a melanoma tumour model. Eur Radiol (2014) 0.75
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol (2004) 8.83
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 5.27
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol (2006) 4.64
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol (2010) 4.62
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res (2007) 4.45
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 4.43
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol (2007) 4.40
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 4.34
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 4.29
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 4.12
Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol (2003) 4.07
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol (2006) 3.81
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol (2009) 3.51
Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology (2005) 3.51
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol (2007) 3.45
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst (2012) 3.16
Sunitinib efficacy against advanced renal cell carcinoma. J Urol (2007) 3.14
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol (2005) 3.12
To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest (2008) 3.05
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol (2008) 2.85
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 2.77
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol (2012) 2.77
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol (2012) 2.75
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 2.72
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials (2008) 2.71
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol (2009) 2.69
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol (2008) 2.68
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl (2010) 2.57
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol (2008) 2.53
Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology (2003) 2.53
Liver fat: effect of hepatic iron deposition on evaluation with opposed-phase MR imaging. Radiology (2007) 2.48
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol (2012) 2.48
Therapy-induced senescence in cancer. J Natl Cancer Inst (2010) 2.45
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
Principles of and advances in percutaneous ablation. Radiology (2011) 2.44
Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology (2005) 2.38
Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol (2005) 2.36
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol (2006) 2.32
[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol (2005) 2.30
Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol (2009) 2.29
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol (2013) 2.29
Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol (2011) 2.25
Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res (2003) 2.25
Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol (2003) 2.22
Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol (2011) 2.21
CT and MR imaging of pericardial disease. Radiographics (2003) 2.19
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol (2007) 2.16
Accuracy and precision of quantitative assessment of cartilage morphology by magnetic resonance imaging at 3.0T. Arthritis Rheum (2005) 2.15
Pulmonary thermal ablation: comparison of radiofrequency and microwave devices by using gross pathologic and CT findings in a swine model. Radiology (2009) 2.12
Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.12
Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res (2004) 2.10
The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther (2006) 2.10
Shock wave lithotripsy success determined by skin-to-stone distance on computed tomography. Urology (2005) 2.08
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg (2005) 2.07
Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res (2009) 2.06
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol (2005) 2.06
Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol (2012) 2.05
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Development of anatomically realistic numerical breast phantoms with accurate dielectric properties for modeling microwave interactions with the human breast. IEEE Trans Biomed Eng (2008) 2.01
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer (2012) 2.01
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl Med Biol (2006) 1.98
Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol (2004) 1.98
Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A (2011) 1.97
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther (2013) 1.90
Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol (2005) 1.89
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res (2009) 1.87